Stifel Nicolaus Cuts Pyxis Oncology (NASDAQ:PYXS) Price Target to $8.00

Pyxis Oncology (NASDAQ:PYXS) had its price objective reduced by Stifel Nicolaus from $9.00 to $8.00 in a research report report published on Tuesday morning,Benzinga reports. They currently have a buy rating on the stock.

Several other equities research analysts also recently commented on the company. HC Wainwright reiterated a “buy” rating and set a $7.00 target price on shares of Pyxis Oncology in a report on Tuesday. Stephens increased their price objective on shares of Pyxis Oncology from $5.00 to $8.00 and gave the company an “overweight” rating in a research report on Monday, November 24th. Wall Street Zen lowered shares of Pyxis Oncology from a “hold” rating to a “sell” rating in a research note on Sunday, March 15th. Royal Bank Of Canada reduced their target price on shares of Pyxis Oncology from $8.00 to $5.00 and set an “outperform” rating on the stock in a research report on Thursday, December 18th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Pyxis Oncology in a research note on Thursday, January 22nd. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Pyxis Oncology currently has a consensus rating of “Moderate Buy” and an average price target of $7.00.

Pyxis Oncology Trading Down 2.8%

Shares of Pyxis Oncology stock opened at $1.39 on Tuesday. Pyxis Oncology has a twelve month low of $0.83 and a twelve month high of $5.55. The stock has a market cap of $87.33 million, a price-to-earnings ratio of -1.08 and a beta of 1.45. The company has a fifty day moving average price of $1.50 and a 200 day moving average price of $2.50.

Pyxis Oncology (NASDAQ:PYXS) last released its quarterly earnings data on Monday, March 23rd. The company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.06. The company had revenue of $11.04 million during the quarter, compared to analysts’ expectations of $0.13 million. Analysts forecast that Pyxis Oncology will post -1.04 earnings per share for the current year.

Institutional Trading of Pyxis Oncology

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Laurion Capital Management LP boosted its stake in Pyxis Oncology by 32.3% during the 4th quarter. Laurion Capital Management LP now owns 4,796,479 shares of the company’s stock valued at $5,516,000 after acquiring an additional 1,170,505 shares during the last quarter. Atle Fund Management AB acquired a new stake in shares of Pyxis Oncology in the 4th quarter valued at about $710,000. Bank of America Corp DE raised its stake in shares of Pyxis Oncology by 2,690.9% in the 3rd quarter. Bank of America Corp DE now owns 615,922 shares of the company’s stock valued at $1,367,000 after purchasing an additional 593,853 shares in the last quarter. Longaeva Partners L.P. bought a new position in shares of Pyxis Oncology during the third quarter worth about $1,117,000. Finally, Jane Street Group LLC lifted its position in shares of Pyxis Oncology by 158.8% during the fourth quarter. Jane Street Group LLC now owns 786,010 shares of the company’s stock worth $904,000 after purchasing an additional 482,310 shares during the last quarter. Institutional investors own 39.09% of the company’s stock.

Pyxis Oncology News Roundup

Here are the key news stories impacting Pyxis Oncology this week:

• Positive Sentiment: HC Wainwright reiterated a “Buy” and lifted several EPS estimates (FY2026→-0.95 from -1.28; FY2027→-0.85; FY2028→-0.34; FY2029→0.27; FY2030→0.83) while keeping a $7 price target — a clear bullish signal for future earnings trajectory. Read More.
• Positive Sentiment: Recent quarter: Pyxis reported a beat on the March quarter EPS (-$0.29 vs. -$0.35 consensus) and $11.0M revenue, which supports the analyst upgrades and contributed to improved sentiment. Read More.
• Neutral Sentiment: Analyst coverage remains mixed overall — consensus is still a “Moderate Buy” with an average $7.00 target, but ratings and targets vary across shops (five Buys, one Hold, one Sell), so conviction is not uniform. Read More.
• Negative Sentiment: Insider selling: Director Rachel Humphrey disclosed multiple sales (most recently 13,896 shares at about $1.03). Insider exits can weigh on sentiment even if done for liquidity reasons; SEC Form 4 is filed. Read More. — SEC filing: Read More.
• Negative Sentiment: Some shops trimmed upside: Stifel reduced its price target (reported recently) which could temper momentum from HC Wainwright’s bullish note. Read More.
• Negative Sentiment: Within HC Wainwright’s note there was a small near‑term downgrade to Q2 2026 EPS (to -$0.36 from -$0.32), a mixed signal for the next quarter despite longer‑term upside revisions. Read More.

About Pyxis Oncology

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.